NCT04518748View on ClinicalTrials.gov

Combined Y-90 Selective Internal Radiation Therapy (Y-90 SIRT) and Stereotactic Body Radiation Therapy (SBRT) in Hepatic Malignancy.

PHASE1RecruitingINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

September 16, 2020

Primary Completion Date

May 31, 2028

Study Completion Date

November 30, 2028

Conditions
Liver Malignancy
Interventions
DRUG

Yttrium-90

Radioactive isotope Y-90 at day 0, administered by selective internal radiation therapy (SIRT)

DEVICE

Selective Internal Radiation Therapy

SIRT at day 0, to administer Yttrium-90 (Y-90) Theraspheres

RADIATION

Stereotactic Body Radiation Therapy

3-5 fractions over 1-2 weeks, after Y-90 SIRT

DIAGNOSTIC_TEST

PET/CT

Within 3 hours of completing Y-90 SIRT

DEVICE

Therasphere

Glass microspheres containing Y-90, administered at day 0 by SIRT

Trial Locations (1)

48109

RECRUITING

University of Michigan Rogel Cancer Center, Ann Arbor

All Listed Sponsors
collaborator

Department of Health and Human Services

FED

collaborator

National Institute for Biomedical Imaging and Bioengineering (NIBIB)

NIH

lead

University of Michigan Rogel Cancer Center

OTHER